AAAAAA

   
Results: 1-19 |
Results: 19

Authors: Burger, AM Mengs, U Schuler, JB Fiebig, HH
Citation: Am. Burger et al., Anticancer activity of an aqueous mistletoe extract (AME) in syngeneic murine tumor models, ANTICANC R, 21(3B), 2001, pp. 1965-1968

Authors: Lerchen, HG Baumgarten, J von dem Bruch, K Lehmann, TE Sperzel, M Kempka, G Fiebig, HH
Citation: Hg. Lerchen et al., Design and optimization of 20-O-linked camptothecin glycoconjugates as anticancer agents, J MED CHEM, 44(24), 2001, pp. 4186-4195

Authors: Easmon, J Purstinger, G Heinisch, G Roth, T Fiebig, HH Holzer, W Jager, W Jenny, M Hofmann, J
Citation: J. Easmon et al., Synthesis, cytotoxicity, and antitumor activity of copper(II) and iron(II)complexes of N-4-azabicyclo[3.2.2]nonane thiosemicarbazones derived from acyl diazines, J MED CHEM, 44(13), 2001, pp. 2164-2171

Authors: Easmon, J Puerstinger, G Roth, T Fiebig, HH Jenny, M Jaeger, W Heinisch, G Hofmann, J
Citation: J. Easmon et al., 2-benzoxazolyl and 2-benzimidazolyl hydrazones derived from 2-acetylpyridine: A novel class of antitumor agents, INT J CANC, 94(1), 2001, pp. 89-96

Authors: Burger, AM Hartung, G Stehle, G Sinn, H Fiebig, HH
Citation: Am. Burger et al., Pre-clinical evaluation of a methotrexate-albumin conjugate (MTX-HSA) in human tumor xenografts in vivo, INT J CANC, 92(5), 2001, pp. 718-724

Authors: Phillips, RM Burger, AM Fiebig, HH Double, JA
Citation: Rm. Phillips et al., Genotyping of NAD(P)H : quinone oxidoreductase (NQO1) in a panel of human tumor xenografts: relationship between genotype status, NQO1 activity and the response of xenografts to Mitomycin C chemotherapy in vivo, BIOCH PHARM, 62(10), 2001, pp. 1371-1377

Authors: Burger, AM Mengs, U Schuler, JB Fiebig, HH
Citation: Am. Burger et al., Antiproliferative activity of an aqueous mistletoe extract in human tumor cell lines and xenografts in vitro, ARZNEI-FOR, 51(9), 2001, pp. 748-757

Authors: Manzotti, C Pratesi, G Menta, E Di Domenico, R Cavalletti, E Fiebig, HH Kelland, LR Farrell, N Polizzi, D Supino, R Pezzoni, G Zunino, F
Citation: C. Manzotti et al., BBR 3464: A novel triplatinum complex, exhibiting a preclinical profile ofantitumor efficacy different from cisplatin, CLIN CANC R, 6(7), 2000, pp. 2626-2634

Authors: Kratz, F Roth, T Fichiner, I Schumacher, P Fiebig, HH Unger, C
Citation: F. Kratz et al., In vitro and in vivo efficacy of acid-sensitive transferrin and albumin doxorubicin conjugates in a human xenograft panel and in the MDA-MB-435 mammacarcinoma model, J DRUG TAR, 8(5), 2000, pp. 305-318

Authors: Fiebig, HH Dengler, W Hendriks, HR
Citation: Hh. Fiebig et al., No evidence of tumor growth stimulation in human tumors in vitro followingtreatment with recombinant human growth hormone, ANTI-CANC D, 11(8), 2000, pp. 659-664

Authors: Weissenberger, C Fiebig, HH Lutterbach, J Barke, A Momm, F Muller, M Witucki, G Guttenberger, R Berger, DP
Citation: C. Weissenberger et al., Is there any correlation between MDR1, GST-pi-expression and CEA?, ANTICANC R, 20(6D), 2000, pp. 5139-5144

Authors: Renneberg, B Li, YM Laatsch, H Fiebig, HH
Citation: B. Renneberg et al., A short and efficient transformation of rhamnose into activated daunosamine, acosamine, ristosamine and epi-daunosamine derivatives, and synthesis ofan anthracycline antibiotic acosaminyl-epsilon-iso-rhodomycinone, CARBOHY RES, 329(4), 2000, pp. 861-872

Authors: Phillips, RM Burger, AM Loadman, PM Jarrett, CM Swaine, DJ Fiebig, HH
Citation: Rm. Phillips et al., Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: Implications for enzyme-directed bioreductive drug development, CANCER RES, 60(22), 2000, pp. 6384-6390

Authors: Hartung, G Stehle, G Sinn, H Wunder, A Schrenk, HH Heeger, S Kranzle, M Edler, L Frei, E Fiebig, HH Heene, DL Maier-Borst, W Queisser, W
Citation: G. Hartung et al., Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients, CLIN CANC R, 5(4), 1999, pp. 753-759

Authors: Rodrigues, PCA Beyer, U Schumacher, P Roth, T Fiebig, HH Unger, C Messori, L Orioli, P Paper, DH Mulhaupt, R Kratz, F
Citation: Pca. Rodrigues et al., Acid-sensitive polyethylene glycol conjugates of doxorubicin: Preparation,in vitro efficacy and intracellular distribution, BIO MED CH, 7(11), 1999, pp. 2517-2524

Authors: Hill, BT Fiebig, HH Waud, WR Poupon, MF Colpaert, F Kruczynski, A
Citation: Bt. Hill et al., Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts, EUR J CANC, 35(3), 1999, pp. 512-520

Authors: Hendriks, HR Fiebig, HH Giavazzi, R Langdon, SP Jimeno, JM Faircloth, GT
Citation: Hr. Hendriks et al., High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer, ANN ONCOL, 10(10), 1999, pp. 1233-1240

Authors: Mross, K Berdel, WE Fiebig, HH Velagapudi, R von Broen, IM Unger, C
Citation: K. Mross et al., Clinical and pharmacologic phase I study of Cemadotin-HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer, ANN ONCOL, 9(12), 1998, pp. 1323-1330

Authors: Rassmann, I Thodtmann, R Mross, M Huttmann, A Berdel, WE Manegold, C Fiebig, HH Kaeser-Frohlich, A Burk, K Hanauske, AR
Citation: I. Rassmann et al., Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion, INV NEW DR, 16(4), 1998, pp. 319-324
Risultati: 1-19 |